ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service


In addition to the 3 rare disease studies, a 4th Novartis study on symptomatic osteoarthritis of the knee was authorized by the Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS) in record time via the CATALIS FAST TRACK Evaluation Service.

In the ONWARDS phase II study, Novartis and Dr. Hughes Allard-Chamard are assessing the efficacy, safety, and tolerance of intraarticular LNA043 treatment regimens compared to placebos in patients with symptomatic osteoarthritis of the knee. This study, which is being conducted in 107 sites in 17 countries and aims to recruit 550 patients, was authorized in 9 weeks by the Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier de l’Université de Sherbrooke Integrated Health and Social Services Centre – Sherbrooke University Health Centre (CIUSSS de l’Estrie – CHUS).

Hughes Allard-Chamard




“We are very pleased to see a remarkable acceleration in the speed at which this clinical trial was approved, thanks to CATALIS Quebec’s FAST TRACK Evaluation Service.” – Dr Hughes Allard-Chamard, researcher at the CIUSS de l’Estrie – Centre hospitalier de l’Université de Sherbrooke 




“The Arthritis Society Canada is pleased to see the launch of an international clinical trial on osteoarthritis through CATALIS’ FAST TRACK Evaluation Service. We welcome this milestone in the name of the more than four million Canadians (1 in 7 adults) living with osteoarthritis, the most common form of arthritis. As the largest charitable source of financing for cutting-edge research in Quebec and Canada, we know how important it is to support our communities of researchers and clinicians who are working to deepen our understanding of arthritis and find effective ways to treat its symptoms and, eventually, discover a potential cure. CATALIS’ FAST TRACK Evaluation Service sets new standards for speed and cooperation in clinical trials from which all Quebecers and Canadians benefit.” – Sian Bevan, Ph.D., Chief Science Officer, Arthritis Society Canada 


The CATALIS’ FAST TRACK Evaluation Service has so far activated 11 clinical trials. Thanks to the commitment of its Network of partners, CATALIS is pleased to continue building on this momentum and reduce the approval times of clinical trials by almost 75% in order to accelerate the development of potential innovative treatments for patients.


If you are a pharmaceutical company and would like more information about the FAST TRACK Evaluation Service, please write to us at info@catalisquebec.com